分子生物学在胰腺癌治疗中的作用

IF 2.5 4区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

World Journal of Gastrointestinal Oncology Pub Date : 2024-07-15 DOI:10.4251/wjgo.v16.i7.2902

A. Boilève, C. Smolenschi, A. Lambert, V. Boige, A. Tarabay, M. Valéry, A. Fuerea, T. Pudlarz, Thierry Conroy, A. Hollebecque, M. Ducreux

{"title":"分子生物学在胰腺癌治疗中的作用","authors":"A. Boilève, C. Smolenschi, A. Lambert, V. Boige, A. Tarabay, M. Valéry, A. Fuerea, T. Pudlarz, Thierry Conroy, A. Hollebecque, M. Ducreux","doi":"10.4251/wjgo.v16.i7.2902","DOIUrl":null,"url":null,"abstract":"Pancreatic ductal adenocarcinoma (PDAC) presents significant challenges in patient management due to a dismal prognosis, increasing incidence, and limited treatment options. In this regard, precision medicine, which personalizes treatments based on tumour molecular characteristics, has gained great interest. However, its widespread implementation is not fully endorsed in current recommendations. This review explores key molecular alterations in PDAC, while emphasizing differences between KRAS -mutated and KRAS -wild-type tumours. It assesses the practical application of precision medicine in clinical settings and outlines potential future directions with respect to PDAC. Actionable molecular targets are examined with the aim of enhancing our understanding of PDAC molecular biology. Insights from this analysis may contribute to a more refined and personalized approach to pancreatic cancer treatment, ultimately improving patient outcomes.","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Role of molecular biology in the management of pancreatic cancer\",\"authors\":\"A. Boilève, C. Smolenschi, A. Lambert, V. Boige, A. Tarabay, M. Valéry, A. Fuerea, T. Pudlarz, Thierry Conroy, A. Hollebecque, M. Ducreux\",\"doi\":\"10.4251/wjgo.v16.i7.2902\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Pancreatic ductal adenocarcinoma (PDAC) presents significant challenges in patient management due to a dismal prognosis, increasing incidence, and limited treatment options. In this regard, precision medicine, which personalizes treatments based on tumour molecular characteristics, has gained great interest. However, its widespread implementation is not fully endorsed in current recommendations. This review explores key molecular alterations in PDAC, while emphasizing differences between KRAS -mutated and KRAS -wild-type tumours. It assesses the practical application of precision medicine in clinical settings and outlines potential future directions with respect to PDAC. Actionable molecular targets are examined with the aim of enhancing our understanding of PDAC molecular biology. Insights from this analysis may contribute to a more refined and personalized approach to pancreatic cancer treatment, ultimately improving patient outcomes.\",\"PeriodicalId\":23762,\"journal\":{\"name\":\"World Journal of Gastrointestinal Oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2024-07-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"World Journal of Gastrointestinal Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.4251/wjgo.v16.i7.2902\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Gastrointestinal Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4251/wjgo.v16.i7.2902","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

胰腺导管腺癌（PDAC）由于预后不良、发病率上升和治疗方案有限，给患者管理带来了巨大挑战。在这方面，根据肿瘤分子特征进行个性化治疗的精准医疗受到了极大关注。然而，目前的建议并未完全认可其广泛实施。本综述探讨了 PDAC 的关键分子改变，同时强调了 KRAS 突变型和 KRAS 野生型肿瘤之间的差异。它评估了精准医疗在临床环境中的实际应用，并概述了 PDAC 潜在的未来发展方向。对可采取行动的分子靶点进行了研究，旨在加深我们对 PDAC 分子生物学的了解。分析得出的见解可能有助于采用更精细、更个性化的方法来治疗胰腺癌，最终改善患者的预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Role of molecular biology in the management of pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) presents significant challenges in patient management due to a dismal prognosis, increasing incidence, and limited treatment options. In this regard, precision medicine, which personalizes treatments based on tumour molecular characteristics, has gained great interest. However, its widespread implementation is not fully endorsed in current recommendations. This review explores key molecular alterations in PDAC, while emphasizing differences between KRAS -mutated and KRAS -wild-type tumours. It assesses the practical application of precision medicine in clinical settings and outlines potential future directions with respect to PDAC. Actionable molecular targets are examined with the aim of enhancing our understanding of PDAC molecular biology. Insights from this analysis may contribute to a more refined and personalized approach to pancreatic cancer treatment, ultimately improving patient outcomes.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

World Journal of Gastrointestinal Oncology Medicine-Gastroenterology

CiteScore

4.20

自引率

3.30%

发文量

1082

期刊介绍： The World Journal of Gastrointestinal Oncology (WJGO) is a leading academic journal devoted to reporting the latest, cutting-edge research progress and findings of basic research and clinical practice in the field of gastrointestinal oncology.